The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > BUSINESS
BUSINESS
- Ajinomoto to Acquire US Gene Therapy CDMO for US$554 Million
November 14, 2023
- UCB Seeks Hidradenitis Suppurativa Nod for Bimzelx in Japan
November 13, 2023
- Otsuka Files NDA for Lupus Nephritis Drug in Japan
November 13, 2023
- Takeda Scores 1st US Nod for Ultra-Rare Blood Clotting Disorder
November 13, 2023
- Daiichi Sankyo’s FLT3 Inhibitor Gets EU Approval for 1st Line AML
November 10, 2023
- Takeda Gets US Clearance for Hutchmed’s Colorectal Cancer Drug
November 10, 2023
- Middle East Unrest Threatens Supply of Kaken’s Burn Eschar Remover
November 9, 2023
- Mitsubishi Licenses Neuropsychiatric Drug to Dutch Startup Kynexis
November 9, 2023
- Japan Ethical Drug Sales Up 6.8% in September: Crecon
November 9, 2023
- Japan OB/GYN Market Projected at 100 Billion Yen in FY2026: Fuji Keizai
November 9, 2023
- CSL Launches Original Home Delivery Service for Hizentra
November 8, 2023
- Upsher-Smith’s Livalo Generic Hits US Market: Sawai
November 8, 2023
- Eisai CEO Confident of Achieving Leqembi Sales Goal of 10 Billion Yen in FY2023
November 8, 2023
- Keytruda Snares Title in Japan Sales Ranking in October: Encise
November 8, 2023
- 180 Employees Apply for Santen’s Voluntary Buyout Program
November 8, 2023
- Eisai’s H1 Operating Profit Spikes on Lenvima Growth, Divestment Gain
November 8, 2023
- Air Pollutant Might Be to Blame for NDMA Formation in Metformin: Towa Paper
November 7, 2023
- Izervay Slows Geographic Atrophy Lesion Growth through 2 Years: Astellas
November 7, 2023
- Nobelpharma Seeks Provisional Disposition against Sawai’s Nobelzin Copy
November 7, 2023
- Chugai Offloading Xeloda to Cheplapharm after German Firm Plants Flag in Japan
November 7, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…